Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Small Cell Lung Cancer (SCLC)
DRUG: Tarlatamab|DRUG: Lurbinectedin|DRUG: Topotecan|DRUG: Amrubicin
Overall Survival (OS), Up to approximately 4 years
Progression Free Survival (PFS), Up to approximately 4 years|Change from Baseline In Selected Functional Scales and Disease Symptom Items Included in Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Up to approximately 4 years|Change from Baseline in Selected Disease Symptoms Included in Lung Cancer Quality of Life Questionnaire (EORTC-QLQ-LC13), Up to approximately 4 years|Overall Response (OR), Up to approximately 4 years|Disease Control (DC), Up to approximately 4 years|Duration of Response (DOR), Up to approximately 4 years|PFS, 1 year|OS, 1 year, 2 years and 3 years|Incidence of Treatment-Emergent Adverse Events (TEAE), Up to approximately 4 years|Serum Concentrations of Tarlatamab, Up to 1 year|Number of Participants Who Experience Anti-tarlatamab Antibodies, Up to 1 year|Change from Baseline in Pain Severity as Measured by Brief Pain Inventory - Short Form (BPI-SF), Up to approximately 4 years|Patient Perceived Health at Each Assessment Visit Using Visual Analogue Scale (VAS), Up to approximately 4 years|Change from Baseline in Patient Perceived Health Using Visual Analog Scale (VAS), Up to approximately 4 years|Responses to Patient-Reported Adverse Events Questionnaire (PRO-CTCAE), Up to approximately 4 years|Change from Baseline in Symptom Severity as Measured by Patient Global Impression of Severity (PGIS) Questionnaire, Up to approximately 4 years|Change from Baseline in Symptoms and Overall Status as Measured by Patient Reported Impression of Change (PGIC) Questionnaire, Up to approximately 4 years|Change from Baseline in Symptom Bother as Measured by Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire, Up to approximately 4 years
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).